Crossject
Develops emergency medications delivered via a needle-free auto-injector platform.
ALCJ | PA
Overview
Corporate Details
- ISIN(s):
- FR0004178614 (+6 more)
- LEI:
- 969500W1VTFNL2D85A65
- Country:
- France
- Address:
- 6 Rue Pauline Kergomard, 21000 dijon
- Website:
- https://www.crossject.com/en
- Sector:
- Manufacturing
Description
Crossject is a specialty pharmaceutical company focused on developing and commercializing medications for life-threatening emergency situations. The company's core technology is ZENEO®, a proprietary, pre-filled, single-use needle-free auto-injector. This platform is designed to enable patients or untrained caregivers to rapidly, safely, and reliably administer emergency treatments. Crossject's product pipeline targets critical conditions such as epileptic seizures, acute adrenal crisis, and severe allergic reactions (anaphylaxis), aiming to improve patient outcomes by simplifying drug delivery in urgent scenarios.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-15 07:30 |
CROSSJECT’s ZENEO® needle-free autoinjector consistently matches depth of trad…
|
English | 148.5 KB | ||
| 2025-05-07 07:30 |
CROSSJECT provides updates on the EUA filing of ZEPIZURE®
|
English | 130.6 KB | ||
| 2025-05-07 07:30 |
CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande …
|
English | 130.6 KB | ||
| 2025-05-06 17:37 |
Crossject : Information relative au nombre total de droits de vote et d'actions…
|
French | 152.7 KB | ||
| 2025-05-06 17:35 |
Crossject : Information relative au nombre total de droits de vote et d'actions…
|
French | 152.7 KB | ||
| 2025-04-30 17:45 |
Mise à disposition du rapport financier annuel 2024
|
French | 506.1 KB | ||
| 2025-04-30 17:45 |
Mise à disposition du rapport financier annuel 2024
|
French | 506.1 KB | ||
| 2025-04-09 17:35 |
Patrick ALEXANDRE, Fondateur et PDG, revient sur le point d’étape publié lors d…
|
French | 125.3 KB | ||
| 2025-03-27 07:30 |
CROSSJECT publie ses résultats financiers pour 2024
|
French | 241.3 KB | ||
| 2025-03-27 07:30 |
CROSSJECT reports financial results for 2024
|
English | 229.4 KB | ||
| 2025-03-25 07:30 |
CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et…
|
French | 130.8 KB | ||
| 2025-03-25 07:30 |
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the …
|
English | 131.1 KB | ||
| 2025-03-18 17:35 |
CROSSJECT franchit une étape clé dans la stabilité des lots produits de ZEPIZUR…
|
French | 123.5 KB | ||
| 2025-03-18 17:35 |
CROSSJECT achieves key ZEPIZURE® manufacturing batch stability milestones
|
English | 121.5 KB | ||
| 2025-03-10 14:17 |
Crossject : Information relative au nombre total de droits de vote et d'actions…
|
French | 182.5 KB |
Automate Your Workflow. Get a real-time feed of all Crossject filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Crossject
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Crossject via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-24 | N/A | Other | Buy | 20,000 | N/A |
| 2024-06-14 | N/A | Other | Other | 10,979 | 20,289.19 EUR |
| 2024-06-06 | N/A | Other | Other | 1,058,617 | 1,956,324.22 EUR |
| 2024-06-06 | N/A | Other | Other | 16,106 | 29,763.89 EUR |
| 2024-06-06 | N/A | Other | Other | 10,275 | 18,988.20 EUR |
| 2024-06-06 | N/A | Other | Other | 10,074 | 18,616.75 EUR |
| 2024-06-06 | N/A | Other | Buy | 5,536 | 10,230.53 EUR |
| 2023-03-06 | N/A | Other | Other | 22,859 | 75,434.70 EUR |
Peer Companies
